Hermanowicz, J.M.;                     Kalaska, B.;                     Pawlak, K.;                     Sieklucka, B.;                     Miklosz, J.;                     Mojzych, M.;                     Pawlak, D.    
        Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. Pharmaceutics 2021, 13, 1222.
    https://doi.org/10.3390/pharmaceutics13081222
    AMA Style
    
                                Hermanowicz JM,                                 Kalaska B,                                 Pawlak K,                                 Sieklucka B,                                 Miklosz J,                                 Mojzych M,                                 Pawlak D.        
                Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. Pharmaceutics. 2021; 13(8):1222.
        https://doi.org/10.3390/pharmaceutics13081222
    
    Chicago/Turabian Style
    
                                Hermanowicz, Justyna Magdalena,                                 Bartlomiej Kalaska,                                 Krystyna Pawlak,                                 Beata Sieklucka,                                 Joanna Miklosz,                                 Mariusz Mojzych,                                 and Dariusz Pawlak.        
                2021. "Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer" Pharmaceutics 13, no. 8: 1222.
        https://doi.org/10.3390/pharmaceutics13081222
    
    APA Style
    
                                Hermanowicz, J. M.,                                 Kalaska, B.,                                 Pawlak, K.,                                 Sieklucka, B.,                                 Miklosz, J.,                                 Mojzych, M.,                                 & Pawlak, D.        
        
        (2021). Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. Pharmaceutics, 13(8), 1222.
        https://doi.org/10.3390/pharmaceutics13081222